 |
|
Amantadine-Resistant Influenza A in Nursing HomesIdentification of a Resistant Virus Prior to Drug Use
Peter Houck, MD;
Mark Hemphill, MS;
Steve LaCroix, MS;
Denny Hirsh, RN;
Nancy Cox, PhD
Arch Intern Med. 1995;155(5):533-537.
Abstract
| |
Background
Amantadine hydrochloride and rimantadine hydrochloride have been used for treatment and prevention of influenza A infection in nursing home residents. Outbreaks of influenza A (H3N2) virus infection occurred in three nursing homes in Yakima County, Washington, during January 1992. Amantadine was used for case treatment and prophylaxis in all three nursing homes.
Methods
Ten influenza A (H3N2) viruses isolated during the outbreaks were examined for resistance to amantadine and rimantadine by means of an enzyme immunoassay and by sequencing of the viral nucleic acid that encodes the transmembrane domain of the M2 protein.
Results
Five of the outbreak strains were resistant and had the same mutation (position 31, serine to asparagine) in the M2 protein. The resistant viruses included one that had been recovered prior to any use of amantadine and another that was recovered within 48 hours of the first drug administration.
Conclusions
To our knowledge, this is the first report of influenza A virus with RNA sequence—documented resistance to amantadine and rimantadine without exposure to either drug, and the shortest reported period between institution of amantadine therapy and isolation of a resistant influenza A virus strain. These results suggest that surveillance for amantadine- and rimantadine-resistant influenza A is needed, because use of these drugs will probably increase.
(Arch Intern Med. 1995;155:533-537)
Author Affiliations
From the Health Care Financing Administration, Region X, Seattle, Wash (Dr Houck); the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga (Mr Hemphill and Dr Cox); the Virology Laboratory, Public Health Laboratories, Washington State Department of Health, Seattle (Mr LaCroix), and the Yakima (Wash) Health District (Ms Hirsh).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
In Vivo and In Vitro Alterations in Influenza A/H3N2 Virus M2 and Hemagglutinin Genes: Effect of Passage in MDCK-SIAT1 Cells and Conventional MDCK Cells
Li et al.
J. Clin. Microbiol. 2009;47:466-468.
ABSTRACT
| FULL TEXT
Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States
Bright et al.
JAMA 2006;295:891-894.
ABSTRACT
| FULL TEXT
Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir
McKimm-Breschkin et al.
Antimicrob. Agents Chemother. 2003;47:2264-2272.
ABSTRACT
| FULL TEXT
Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2
Saito et al.
J. Clin. Microbiol. 2003;41:2164-2165.
ABSTRACT
| FULL TEXT
Detection of Amantadine-Resistant Influenza A Virus Strains in Nursing Homes by PCR-Restriction Fragment Length Polymorphism Analysis with Nasopharyngeal Swabs
Saito et al.
J. Clin. Microbiol. 2002;40:84-88.
ABSTRACT
| FULL TEXT
Isolation of Amantadine-Resistant Influenza A Viruses (H3N2) from Patients following Administration of Amantadine in Japan
Iwahashi et al.
J. Clin. Microbiol. 2001;39:1652-1653.
ABSTRACT
| FULL TEXT
Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies
Barnett et al.
Antimicrob. Agents Chemother. 2000;44:78-87.
ABSTRACT
| FULL TEXT
Duration of Antiviral Prophylaxis During Nursing Home Outbreaks of Influenza A: A Comparison of 2 Protocols
Drinka et al.
Arch Intern Med 1998;158:2155-2159.
ABSTRACT
| FULL TEXT
|
